246 related articles for article (PubMed ID: 16107580)
1. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
Teutonico A; Schena PF; Di Paolo S
J Am Soc Nephrol; 2005 Oct; 16(10):3128-35. PubMed ID: 16107580
[TBL] [Abstract][Full Text] [Related]
2. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
6. Glucose metabolism before and after conversion from cyclosporine microemulsion to tacrolimus in stable renal recipients.
Gelens MA; Christiaans MH; van Hooff JP
Nephrol Dial Transplant; 2008 Feb; 23(2):701-6. PubMed ID: 17999993
[TBL] [Abstract][Full Text] [Related]
7. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
8. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
[TBL] [Abstract][Full Text] [Related]
9. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
[TBL] [Abstract][Full Text] [Related]
10. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
[TBL] [Abstract][Full Text] [Related]
11. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
[TBL] [Abstract][Full Text] [Related]
12. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy.
Sato T; Inagaki A; Uchida K; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Tominaga Y; Okajima Y; Ohta K; Suga H; Taguchi S; Kakiya S; Itatsu T; Kobayashi T; Nakao A
Transplantation; 2003 Nov; 76(9):1320-6. PubMed ID: 14627910
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
[TBL] [Abstract][Full Text] [Related]
15. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
[TBL] [Abstract][Full Text] [Related]
17. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
[TBL] [Abstract][Full Text] [Related]
19. Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens.
Lee PC; Lee CY; Hu RH; Lo C; Tsai MK; Lee PH
Nephrol Dial Transplant; 2010 May; 25(5):1675-80. PubMed ID: 20042398
[TBL] [Abstract][Full Text] [Related]
20. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
